Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take.
Advertisement
Adjuvant Therapy In RCC: Very Controversial But Needs Continual Development, Sunitinib Therapy Is A Reasonable Approach To Take
By Editor